skip to main content

Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

Recognition and management of severe cutaneous adverse reactions.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MSt MRCGP (General Practitioner)
Last reviewed: 21 October 2025
DermatologyEmergency Medicine
Turn this into CPDPractise this topic, identify learning gaps and prepare a CPD draft you can review.

Clinical Guidelines

British Association of Dermatologists guidelines for the management of Stevens–Johnson syndrome and toxic epidermal necrolysis
National
UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis 2016
National
UK guidelines for the management of Stevens–Johnson syndrome and toxic epidermal necrolysis
National
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Carbamazepine Therapy
Local
S3 guideline: Diagnosis and treatment of epidermal necrolysis including Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) – Short version
Local
Severe Cutaneous Adverse Reactions (SCAR): CIOMS Working Group Draft Report 2024
Local
UK guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016
Local